Combined Oral Contraceptive Effects on Low-Grade Chronic Inflammatory Mediators in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis

Table 3

Summary of the influence of different oral contraceptive combination on C-reactive protein in polycystic ovary syndrome^∗.

Inflammatory marker
Study	Formulation	Before	After	ES^∗∗	p^∗∗∗
CRP (mg/l)
Morin-Papunen et al, 2003	EE 35 μg/ CPA 2 mg	2.91	4.58	+1.67	<0.001
Chen et al, 2010	EE 35 μg/ CPA 2 mg	0.7	1.2	+0.5	0.002
Teede et al, 2010	EE 35 μg/ CPA 2 mg	3.5	4.7	+1.2	0.001
Ibanez et al, 2011	EE 35 μg/ CPA 2 mg	0.9	1.7	+0.8	<0.05
Gode et al, 2011	EE 35 μg/ CPA 2 mg	3.31	3.87	+0.56	>0.05
Diaz et al, 2012	EE 35 μg/ CPA 2 mg	0.9	2.6	+1.7	<0.05
Ibanez et al, 2013	EE 35 μg/ CPA 2 mg	0.9	3.2	+2.3	<0.01
Christakou et al, 2014	EE 35 μg/ CPA 2 mg	1.36	2.63	+1.27	<0.001
Kahraman et al, 2014	EE 35 μg/ CPA 2 mg	1.21	3.31	+2.1	<0.05
Dardzinska et al, 214	EE 35 μg/ CPA 2 mg	0.77	1.70	+0.93	<0.001
Orio et al, 2016	EE 35 μg/ CPA 2 mg	1.80	1.90	+0.1	>0.05
Tfayli et al, 2011	EE 30 μg/ DRSP 3 mg	1.7	3.8	+2.1	<0.001
Harmanci et al, 2013	EE 30 μg/ DRSP 3 mg	0.50	1.5	+1	<0.05
Kahraman et al, 2014	EE 30 μg/ DRSP 3 mg	0.93	1.22	+0.29	0.040
Christakou et al, 2014	EE 30 μg/ DRSP 3 mg	1.09	1.93	+0.84	<0.001
Yildzhan et al, 2015	EE 30 μg/ DRSP 3 mg	3.77	4.32	+0.55	0.005
Orio et al, 2016	EE 30 μg/ DRSP 3 mg	1.8	1.9	+0.1	<0.05
Vieira et al, 2012	EE 30 μg/ CMA 2 mg	2.1	6.0	+3.9	<0.05
Yildzhan et al, 2015	EE 30 μg/ CMA 2 mg	4.26	0.72	-3.54	0.004
Hoeger et al, 2008	EE 30 μg/ DSG 0.15 mg	6.8	9.5	+2.7	<0.05
Kilic et al, 2011	EE 30 μg/ DSG 0.15 mg	1.67	3.23	+1.56	<0.001
Banaszewska et al, 2007	EE 20 μg/ DSG 0.15 mg	1.61	1.70	+0.09	0.74
Essah et al, 2011	EE 30 μg/ DSG 0.15-0.25 mg	4.9	5.6	+0.7	0.280

abbreviations are given in the text.
^∗∗ES: effect-size.
^∗∗∗p: values taken from each study.